KR101402554B1 - β-글루코세레브로시다제의 활성 증진에 의한 신경계 장애 치료 방법 - Google Patents

β-글루코세레브로시다제의 활성 증진에 의한 신경계 장애 치료 방법 Download PDF

Info

Publication number
KR101402554B1
KR101402554B1 KR1020097001465A KR20097001465A KR101402554B1 KR 101402554 B1 KR101402554 B1 KR 101402554B1 KR 1020097001465 A KR1020097001465 A KR 1020097001465A KR 20097001465 A KR20097001465 A KR 20097001465A KR 101402554 B1 KR101402554 B1 KR 101402554B1
Authority
KR
South Korea
Prior art keywords
delete delete
substituted
activity
unsubstituted
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097001465A
Other languages
English (en)
Korean (ko)
Other versions
KR20090021393A (ko
Inventor
브란든 우스트만
Original Assignee
아미쿠스 세라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38834440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101402554(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아미쿠스 세라퓨틱스, 인코포레이티드 filed Critical 아미쿠스 세라퓨틱스, 인코포레이티드
Publication of KR20090021393A publication Critical patent/KR20090021393A/ko
Application granted granted Critical
Publication of KR101402554B1 publication Critical patent/KR101402554B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
KR1020097001465A 2006-06-23 2007-06-25 β-글루코세레브로시다제의 활성 증진에 의한 신경계 장애 치료 방법 Expired - Fee Related KR101402554B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81595206P 2006-06-23 2006-06-23
US60/815,952 2006-06-23
PCT/US2007/072016 WO2007150064A2 (en) 2006-06-23 2007-06-25 METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE

Publications (2)

Publication Number Publication Date
KR20090021393A KR20090021393A (ko) 2009-03-03
KR101402554B1 true KR101402554B1 (ko) 2014-06-19

Family

ID=38834440

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097001465A Expired - Fee Related KR101402554B1 (ko) 2006-06-23 2007-06-25 β-글루코세레브로시다제의 활성 증진에 의한 신경계 장애 치료 방법

Country Status (15)

Country Link
US (4) US7829579B2 (https=)
EP (1) EP2040548B1 (https=)
JP (1) JP5303458B2 (https=)
KR (1) KR101402554B1 (https=)
AT (1) ATE555788T1 (https=)
AU (1) AU2007260812B2 (https=)
BR (1) BRPI0713442A2 (https=)
CA (1) CA2656643C (https=)
DK (1) DK2040548T3 (https=)
ES (1) ES2387845T3 (https=)
IL (1) IL196151A (https=)
MX (1) MX2009000032A (https=)
PT (1) PT2040548E (https=)
WO (1) WO2007150064A2 (https=)
ZA (1) ZA200900270B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
WO2007150064A2 (en) 2006-06-23 2007-12-27 Amicus Therapeutics, Inc. METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE
GB0622702D0 (en) * 2006-11-15 2006-12-27 Univ Dundee Selective glycosidase inhibitors
EP2154969B1 (en) 2007-05-16 2015-11-18 The Brigham and Women's Hospital, Inc. Treatment of synucleinopathies
US8540985B2 (en) * 2008-06-26 2013-09-24 Orphazyme Aps Use of Hsp70 as a regulator of enzymatic activity
GB2480159A (en) * 2008-11-14 2011-11-09 Parkinson S Inst Compositions and methods for the treatment of altered a-synuclein function
BRPI1010517A2 (pt) * 2009-04-09 2017-01-31 Amicus Therapeutics Inc métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal
BRPI1015472A2 (pt) * 2009-04-09 2015-11-24 Amicus Therapeutics Inc métodos para prevenção e/ou tratamento de doenças degenerativas do sistema nervoso central
GB0906159D0 (en) * 2009-04-09 2009-05-20 Summit Corp Plc Drug combination for the treatment of proteostatic diseases
US9206457B2 (en) * 2009-05-26 2015-12-08 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
AU2010254092B2 (en) * 2009-05-26 2015-11-12 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
NZ713967A (en) * 2009-07-28 2017-01-27 Shire Human Genetic Therapies Compositions and methods for treating gaucher disease
KR101880411B1 (ko) 2009-10-19 2018-07-19 아미쿠스 세라퓨틱스, 인코포레이티드 중추신경계의 퇴행성 질환을 예방 및/또는 치료하는 신규 조성물
US9044437B2 (en) * 2009-10-19 2015-06-02 Amicus Therapeutics, Inc. Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases
SI2995306T1 (sl) 2009-10-19 2019-04-30 Amicus Therapeutics, Inc. Novi sestavki za preprečevanje in/ali zdravljenje motenj lizosomskega shranjevanja
RU2013125923A (ru) 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
HUE044867T2 (hu) 2011-05-12 2019-11-28 Proteostasis Therapeutics Inc Proteosztázis szabályzók
EP2533051A1 (en) 2011-06-06 2012-12-12 Centogene GmbH Method for the diagnosis of Gaucher's disease
CA2840224C (en) 2011-06-22 2019-08-13 The General Hospital Corporation Treatment of proteinopathies
EP2806875B1 (en) 2012-01-25 2017-07-19 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
AU2013337354A1 (en) * 2012-11-05 2015-05-21 Genzyme Corporation Compositions and methods for treating proteinopathies
WO2014089449A1 (en) * 2012-12-07 2014-06-12 Rush University Nedical Center Composition and method for treating neuronal ceroid lipofuscinosis
US9796680B2 (en) 2013-12-23 2017-10-24 Alectos Therapeutics Inc. Glucocerebrosidase modulators and uses thereof
US9675627B2 (en) 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
EP4406616A3 (en) 2014-11-06 2024-11-06 Bial-R&D Investments, S.A. Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
CA2985235A1 (en) 2015-05-07 2016-11-10 Shire Human Genetic Therapies, Inc. Glucocerebrosidase gene therapy for parkinson's disease
AU2017246455B2 (en) 2016-04-06 2021-09-30 Bial - R&D Investments, S.A. Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3440081A4 (en) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
CA3020305A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
KR20210059796A (ko) 2016-04-29 2021-05-25 오르파짐 에이/에스 글루코세레브로시다제 연관 장애를 치료하기 위한 아리모클로몰
KR102530515B1 (ko) 2016-05-05 2023-05-09 비알 - 알&디 인베스트먼츠, 에스.에이. 치환된 이미다조[1,2-b]피리다진, 치환된 이미다조[1,5-b]피리다진, 관련 화합물, 및 의학적 장애의 치료에서의 그의 용도
EP3264092A1 (en) * 2016-07-01 2018-01-03 Centogene AG Use of lyso-gb1 as druggable target
KR20240171186A (ko) 2017-10-26 2024-12-06 다케다 야쿠힌 고교 가부시키가이샤 글루코세레브로시다제 및 이소파고민을 포함하는 제제
CN108428452B (zh) 2018-03-14 2019-12-13 百度在线网络技术（北京）有限公司 终端支架和远场语音交互系统
WO2020006269A1 (en) 2018-06-27 2020-01-02 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
JP7561632B2 (ja) 2018-06-27 2024-10-04 キネタ， インコーポレイテッド プロテアソーム活性増強化合物
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
SG11202105606XA (en) * 2018-12-05 2021-06-29 Univ Washington Methods of detecting, preventing, reversing, and treating neurological diseases
WO2020219874A1 (en) * 2019-04-25 2020-10-29 Shire Human Genetic Therapies, Inc. Isofagomine salts, methods of use and formulations
CN111450306B (zh) * 2020-03-06 2021-11-19 大连理工大学 外用纳米羟基磷灰石/聚多巴胺湿黏附型止血粉及其制备方法
KR20230128462A (ko) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정
EP4329881A4 (en) * 2021-04-30 2025-06-11 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119874A1 (en) * 1998-06-01 2003-06-26 Mount Sinai School Of Medicine Method for enhancing mutant enzyme activity in gaucher disease
WO2004069190A2 (en) * 2003-01-31 2004-08-19 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiency disorders
WO2006133446A2 (en) * 2005-06-08 2006-12-14 Amicus Therapeutics, Inc. Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2268904A1 (en) * 1996-10-15 1998-04-23 Imperial College Of Science, Technology And Medicine Diagnosis of spongiform encephalopathy
GB2333362B (en) 1996-10-15 2001-05-16 Imperial College Typing and diagnosis of spongiform encephalopathy
CA2545433A1 (en) 2003-11-12 2005-05-26 Amicus Therapeutics Inc. Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
PL1860101T3 (pl) * 2006-05-24 2011-10-31 Amicus Therapeutics Inc Sól winianu izofagominy i sposoby zastosowania
WO2007150064A2 (en) 2006-06-23 2007-12-27 Amicus Therapeutics, Inc. METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE
CA2688850C (en) 2007-05-22 2015-08-11 Amicus Therapeutics, Inc. New method for preparing isofagomine and its derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119874A1 (en) * 1998-06-01 2003-06-26 Mount Sinai School Of Medicine Method for enhancing mutant enzyme activity in gaucher disease
WO2004069190A2 (en) * 2003-01-31 2004-08-19 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiency disorders
WO2006133446A2 (en) * 2005-06-08 2006-12-14 Amicus Therapeutics, Inc. Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes

Also Published As

Publication number Publication date
US20110052613A1 (en) 2011-03-03
AU2007260812B2 (en) 2012-08-16
ZA200900270B (en) 2011-02-23
DK2040548T3 (da) 2012-08-13
AU2007260812A1 (en) 2007-12-27
IL196151A0 (en) 2009-11-18
US20080009516A1 (en) 2008-01-10
IL196151A (en) 2015-08-31
JP5303458B2 (ja) 2013-10-02
CA2656643A1 (en) 2007-12-27
KR20090021393A (ko) 2009-03-03
EP2040548A2 (en) 2009-04-01
CA2656643C (en) 2015-08-25
US7829579B2 (en) 2010-11-09
US9402837B2 (en) 2016-08-02
ATE555788T1 (de) 2012-05-15
BRPI0713442A2 (pt) 2012-03-06
ES2387845T3 (es) 2012-10-02
PT2040548E (pt) 2012-08-02
JP2009541489A (ja) 2009-11-26
EP2040548B1 (en) 2012-05-02
US9119845B2 (en) 2015-09-01
US20150025109A1 (en) 2015-01-22
US10064851B2 (en) 2018-09-04
WO2007150064A3 (en) 2008-02-21
MX2009000032A (es) 2009-01-23
US20170027919A1 (en) 2017-02-02
EP2040548A4 (en) 2009-12-23
WO2007150064A2 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
KR101402554B1 (ko) β-글루코세레브로시다제의 활성 증진에 의한 신경계 장애 치료 방법
US12599595B2 (en) Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
JP6043316B2 (ja) １−デオキシノジリマイシンおよび誘導体を用いるポンペ病の治療方法
US20100113517A1 (en) Method for the treatment of fabry disease using pharmacological chaperones
AU2008245578A1 (en) Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
KR20080033242A (ko) 리소좀 효소를 코딩하는 유전자의 돌연변이와 관련있는ｃｎｓ 질환의 치료 방법
MX2010009874A (es) Tratamiento para la enfermedad de pompe con chaperonas farmacologicas especificas y monitoreo del tratamiento usando marcadores subrogados.
JP6662789B2 (ja) 脳アミロイドーシスを処置及び／又は予防する投与計画
TW201620517A (zh) 用於治療及／或預防腦澱粉樣變性（Ｃｅｒｅｂｒａｌ Ａｍｙｌｏｉｄｏｓｅｓ）之給藥方案
HK1216230B (en) A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
HK1133789A (en) Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes
HK40004632A (en) A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20170504

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180427

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220527

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220527

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000